Sclerostin and its role in the regulation of bone metabolism

Sclerostin and its role in the regulation of bone metabolism

Bibliographic Details
Main Authors:	Irina Stepanovna Dydykina, E S Vetkova
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2013-06-01
Series:	Научно-практическая ревматология
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1654

Similar Items

Role of sclerostin in mastocytosis bone disease
by: Aneta Szudy-Szczyrek, et al.
Published: (2025-01-01)

Obesity and Bone Loss at Menopause: The Role of Sclerostin
by: Paolo Marzullo, et al.
Published: (2021-10-01)

The role of sclerostin (bone proteins) and its effect on osteoporosis in postmenopausal women
by: Kamel Mohammed Haider, et al.
Published: (2024-01-01)

The roles of sclerostin and irisin on bone and muscle of orchiectomized rats
by: Bing-na Zhou, et al.
Published: (2022-12-01)

Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone
by: Elżbieta Skowrońska-Jóźwiak, et al.
Published: (2015-01-01)

Serum levels of sclerostin in prediabetes and its correlation with bone mineral density
by: Ajay Chauhan, et al.
Published: (2023-11-01)

Sclerostin: clinical insights in muscle–bone crosstalk
by: Antimo Moretti, et al.
Published: (2023-08-01)

Sclerostin
by: Stuart L. Silverman
Published: (2010-01-01)

Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
by: Power, J, et al.
Published: (2010)

Sclerostin expression in bone tumours and tumour-like lesions
by: Inagaki, Y, et al.
Published: (2016)

Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein
by: Nicole R Gould, et al.
Published: (2021-03-01)

B4GALNT3 regulates glycosylation of sclerostin and bone massResearch in context
by: Sofia Movérare-Skrtic, et al.
Published: (2023-05-01)

Serum sclerostin and bone turnover in latent autoimmune diabetes in adults
by: Napoli, N, et al.
Published: (2018)

Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes
by: Piccoli, A, et al.
Published: (2020)

Bone marrow adipoq+ cell population controls bone mass via sclerostin in mice
by: Huanqing Gao, et al.
Published: (2023-07-01)

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
by: Poole, K, et al.
Published: (2005)

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
by: Tao Xiaohui, et al.
Published: (2024-07-01)

Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration
by: Martyna Patalong-Wójcik, et al.
Published: (2023-05-01)

Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency
by: Aleksandra Zdrojowy-Wełna, et al.
Published: (2022-11-01)

Osteocyte sclerostin expression: Regulator of BMU balance in osteoarthritis and osteoporosis?
by: Loveridge, N, et al.
Published: (2007)

Peroxisome proliferator activated receptor-γ in osteoblasts controls bone formation and fat mass by regulating sclerostin expression
by: Soohyun P. Kim, et al.
Published: (2023-07-01)

Is sclerostin expression a common modulator of the effects of osteoporosis and osteoarthritis on bone formation?
by: Loveridge, N, et al.
Published: (2007)

Sclerostin expression by osteocytes is a delayed event; Implications for the control of bone formation
by: Poole, K, et al.
Published: (2005)

Mechanical loading response in trabecular bone is abrogated by sclerostin - A direct demonstration
by: Khalid, Kamarul Ariffin, et al.
Published: (2012)

Anti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration
by: Shruthi Reghunath, et al.
Published: (2024-07-01)

Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk
by: Maria Sara Magarò, et al.
Published: (2021-01-01)

Serum Sclerostin Level Is Negatively Associated with Bone Mineral Density in Hemodialysis Patients
by: Jing-Wun Lu, et al.
Published: (2022-03-01)

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly
by: Jowita Halupczok-Żyła, et al.
Published: (2024-12-01)

Serum sclerostin levels in rheumatoid arthritis and correlation with disease activity and bone mineral density
by: Urmila Dhakad, et al.
Published: (2019-01-01)

Correlation between serum sclerostin level and bone density status in children on regular hemodialysis
by: Manal Abd Elsalam, et al.
Published: (2019-01-01)

IL-1β contributes to the secretion of sclerostin by osteocytes and targeting sclerostin promotes spinal fusion at early stages
by: Zengxin Jiang, et al.
Published: (2023-03-01)

Role of sclerostin, fibroblast growth factor-23, and Klotho in hemodialysis patients
by: Azza A I. Elmenyawi, et al.
Published: (2019-01-01)

Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone
by: Rachel K Surowiec, et al.
Published: (2020-08-01)

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review
by: Venkitachalam Ramanarayanan, et al.
Published: (2022-12-01)

PPARG in osteocytes controls cell bioenergetics and systemic energy metabolism independently of sclerostin levels in circulation
by: Sudipta Baroi, et al.
Published: (2024-10-01)

Co-expression of DKK-1 and sclerostin in subchondral bone of the proximal femoral heads from osteoarthritic hips
by: Zarei, A, et al.
Published: (2017)

Prevalence of low bone mineral density in ankylosing spondylitis, correlation with disease activity, and serum sclerostin levels
by: Anupam Wakhlu, et al.
Published: (2020-01-01)

Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential
by: Amu Gubu, et al.
Published: (2024-03-01)

Relation between serum sclerostin and CTRP3 levels and bone mineral density in diabetic postmenopausal women
by: Inass Hassan Ahmad, et al.
Published: (2024-09-01)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
by: Kelsey A. Carpenter, et al.
Published: (2023-10-01)